It's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a severe form of high cholesterol cut back on pricey and cumbersome aphaeresis treatments, new late-stage study data show. More from FiercePharmaMarketing
@FiercePharma: Intersections snags $20M loan to support struggling Voyce health monitor for dogs. FierceAnimalHealth report | Follow @FiercePharma
@CarlyHFierce: ICYMI: With Cinqair nod, Teva squares off with GSK in severe asthma. Article | Follow @CarlyHFierce
> Steve Ubl, the new CEO of PhRMA, says the lobbying group will take an offensive, rather than defensive, approach to facing issues like concern over pharma price increases. Story
> India's Biocon has gotten approval from Japan for its biosimilar of Sanofi's ($SNY) Lantus, a step Managing Director Kiran Mazumdar-Shaw called a "credibility milestone" for the company. Story
> A Chinese drugmaker says the country needs more homegrown drugs to reduce its dependence on imports. Report
> A study says the risk of death goes way up for patients with Parkinson's disease who are treated with antipsychotic drugs. Blog Post
Medical Device News
@FierceMedDev: ICYMI: Philips shells out $35M to settle sleep apnea mask kickback charges with DOJ. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Article | Follow @VarunSaxena2
@EmilyWFierce: Valeant's wounds bleed onto Ackman's Pershing Square with latest Senate probe. FiercePharma story | Follow @EmilyWFierce
> Ex med tech CEO faces jail time for bribing docs to promote skin-like wound dressing. Report
> Goldman Sachs invests $37M in Chinese TAVR player. Story
> Fed judge rules case against Bayer's Essure birth control device to move forward. Article
Biotech News
@FierceBiotech: UPDATED: FDA's internal review of Acadia's Parkinson's drug raises safety, benefit concerns. Article | Follow @FierceBiotech
@JohnCFierce: From the weekend bureau: Forum faces the end o' the road. Story | Follow @JohnCFierce
> Alder rockets up as promising migraine data heats up a frenzied race for CGRP drug approval. Story
> Under pressure, XenoPort sells U.S. rights of failed psoriasis pill to Dr. Reddy's. Article
> Aduro offers $7.5M to fuel UC Berkeley's immunotherapy research effort. More
Animal Health News
> Akorn emerges from audit with better-than-expected 2015 results. Item
> Neogen plunges on Q3 miss as CEO seeks global growth for gene-testing services. Article
> Genes in canine bone tumors predict drug response: Report. More
> Intersections snags $20M loan to support struggling Voyce health monitor for dogs. News
> Roslin turns to business with new animal health venture. Report
Biotech IT News
> Lundbeck upgrades ArisGlobal regulatory and safety IT system. Item
> 23andMe tech brings genetic data to Apple ResearchKit studies. More
> Overturning bioinformatic predictions, Venter creates minimal synthetic cell with 473 genes. Story
> Sony-backed M3, Endeavour Vision unveil digital health investment funds. Article
> Microsoft co-founder commits $100M to early-stage research at intersection of IT and biology. Report
Pharma Marketing News
> Looking for a respiratory edge, Boehringer teams with Propeller to test 'smart inhaler' for adherence. Article
> Apple's CareKit opens new door for pharma to develop apps, but will it walk through? More
> Could J&J get an image boost from new health-oriented research? Experts say yes. Story
> Novartis kickbacks blows up as feds demand info on 80,000 doc events. Item
And Finally... During a trip to Cuba, Pfizer's Dave Verbraska, VP of worldwide public affairs, found state-run pharmacies, domestically produced generic drugs and few imports. Blog Post